Quarterly report pursuant to Section 13 or 15(d)

Equity and Earnings Per Share - Additional Information (Details)

v3.21.1
Equity and Earnings Per Share - Additional Information (Details) - USD ($)
3 Months Ended
Mar. 15, 2021
Mar. 15, 2021
Mar. 09, 2021
Mar. 31, 2021
Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]          
Proceeds from equity offering, net of offering costs       $ 120,216,000 $ 0
Deducting offering costs     $ 5,542,000    
Net proceeds to repayments       $ 80,000,000  
Class A Common Stock          
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]          
Sale of stock shares issued in transaction (in shares)     2,500,000    
Offering price (in dollar per share)     $ 44.00    
Proceeds from equity offering, net of offering costs     $ 104,458,000    
Class A Common Stock | Over-Allotment Option          
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]          
Sale of stock shares issued in transaction (in shares) 375,000        
Proceeds from equity offering, net of offering costs $ 15,758,000        
Deducting offering costs $ 742,000        
Class A Common Stock | Selling Shareholders          
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]          
Sale of stock shares issued in transaction (in shares)   805,000      
Offering price (in dollar per share) $ 44.00 $ 44.00      
Proceeds from equity offering, net of offering costs   $ 0